Molecular imaging using magnetic resonance: New tools for the development of tumour therapy

British Journal of Radiology

Volumn 76, Issue SPEC. ISS. 2, 2003, Pages

  Brindle, K M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULAR TARGETING AGENT;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL SEPARATION; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG RESPONSE; HUMAN; IMMUNOCOMPETENT CELL; METHODOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT DEPARTMENT; TUMOR CELL; TUMOR REJECTION;

ANIMALS; APOPTOSIS; CELL MOVEMENT; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASMS; RATS;

EID: 8844270879     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/50577981     Document Type: Article

References (61)

1. Bogdanov A, Weissleder R. The development of in vivo imaging systems to study gene expression. Trends Biotech 1998;16:5-10.
2. Weissleder R. Molecular imaging: exploring the next frontier. Radiology 1999;212:609-14.
3. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nature Rev Cancer 2001;2:1-8.
4. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Development 2003;17:545-80.
5. Johnson GA, Cofer G, Gewalt SL, Hedlund LW. Morphologic phenotyping with MR microscopy: the visible mouse. Radiology 2002;222:789-93.
6. Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, Sandford R. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 2001;98:12174-9.
7. Gadian DG, Radda GK. NMR studies of tissue metabolism. Ann Rev Biochem 1981;50:69-83.
8. Radda GK. The use of NMR spectroscopy for the understanding of disease. Science 1986;233:640-5.
9. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-33.
10. Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L, et al. Heterogeneity in apoptosis development in irradiated murine tumours of different histologies. Int J Radiat Biol 1993;64:583-91.
11. Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumours treated with chemotherapy agents. Anticancer Drugs 1995;6:443-50.
12. Dubray B, Breton C, Delic J, Klijanienko J, Maciorowski Z, Vielh P, et al. In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother Oncol 1998;46:185-91.
13. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
14. 31p MRS. Magn Reson Med 1998;40:411-20.
15. Anthony ML, Zhao M, Brindle KM. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem 1999;274:19686-92.
16. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nature Med 1999;5:1323-7.
17. 1H NMR spectra of a myeloma cell line correlates with the induced formation of cytoplasmic lipid droplets. Magn Reson Med 1993;29:546-50.
18. 1H NMR visible lipids in the life and death of cells. Trends Biochem Sci 2000;25: 357-62.
19. Chenevert TL, Stegman LD, Taylor JMG, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36.
20. Hakumaki JM, Grohn OHJ, Tyynela K, Valonen P, Yla-Herttuala S, Kauppinen RA. Early gene therapy-induced apototic response in BT4C gliomas by magnetic resonance relaxation contrast T-1 in the rotating frame. Cancer Gene Ther 2002;9:338-45.
21. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000;405:85-90.
22. Martin SJ, Reutelingsperger CPM, McGahon AJ, Rader JA, Vanschie RCAA, LaFace DM, et al. Early redistribution of plasma-membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus-inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182: 1545-56.
23. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998;95:6349-54.
24. Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for non-invasive detection of cardiac allograft rejection. Nature Med 2001;7: 1347-52.
25. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nature Med 2001;7:1241-4.
26. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nature Med 2003;9:713-25.
27. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med 1994;31:1-8.
28. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discovery Today 2001;6:427-36.
29. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
30. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
31. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Rev Drug Discovery 2002;1:415-26.
32. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997;390:335-6.
33. Brindle KM. Editorial. NMR Biomed 2002;15:87-8.
34. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays a potent and selective toxicity toward tumour vasculature. Cancer Res 1997;57:1829-34.
35. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998;77:1761-7.
36. Galbraith SM, Taylor NJ, Maxwell RJ, Lodge M, Tozer GM, Baddeley H, et al. Combretastatin A4 phosphate (CA4P) targets vasculature in animal and human tumours. Br J Cancer 2000;83 Suppl 1:12.
37. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the anti-vascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-5.
38. Dyke SOM, Beauregard DA, Brindle KM. Modulating tumour sensitivity to the anti-vascular drug combretastatin A4 phosphate. Proc Intl Soc Mag Reson Med 2002;10:2141.
39. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. JMRI 1997;7:68-74.
40. Pham C, Roberts T, van Bruggen N, Melnyk O, Mann J, Ferrara N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-30.
41. 3-targeted magnetic resonance imaging. Nature Med 1998;4:623-6.
42. 3-targeted nanoparticles. Magn Reson Med 2000;44:433-9.
43. Su M-Y, Taylor JA, Villarreal LP, Nalcioglu O. Prediction of gene therapy-induced tumor size changes by the vascularity changes measured using dynamic contrast-enhanced MRI. Magn Reson Imaging 2000;18:311-7.
44. Hu D-E, Beauregard DA, Bearchell MC, Thomsen LL, Brindle KM. Early detection of tumour immune-rejection using magnetic resonance imaging. Br J Cancer 2003;88: 1135-42.
45. Shrikant P, Mescher MF. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol 1999;162:2858-66.
46. Yeh T-C, Zhang W, Ildstad ST, Ho C. In vivo dynamic tracking of rat T-cells labeled with superparamagnetic iron-oxide particles. Magn Reson Med 1995;33:200-8.
47. Moore A, Sun PZ, Cory D, Hogemann D, Weissleder R, Lipes MA. MRI of insulitis in autoimmune diabetes. Magn Reson Med 2002;47:751-8.
48. Orkin SH, Morrison SJ. Biomedicine: stem-cell competition. Nature 2002;418:25-7.
49. Franklin RJM, Blaschuk KL, Bearchell M, Presoz LC, Setzu A, Brindle K, et al. Magnetic resonance imaging of transplanted oligodendrocyte precursors in the rat brain. NeuroReport 1999;10:1-5.
50. Bulte JWM, Zhang S-C, van Gelderen P, Herynek V, Jordan EK, Duncan ID, et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci USA 1999;96:15256-61.
51. Hoehn M, Kustermann E, Blunk J, Wiedermann D, Trapp T, Wecker S, et al. Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc Natl Acad Sci USA 2002;99:16267-72.
52. Hinds KA, Hill JM, Shapiro EM, Laukkanen MO, Silva AC, Combs CA, et al. Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood 2003;102:867-72.
53. Dodd SJ, Williams M, Suhan JP, Williams DS, Koretsky AP, Ho C. Detection of single mammalian cells by high resolution magnetic resonance imaging. Biophys J 1999;76:103-9.
54. Mason WT, editor. Fluorescent and luminescent probes for biological activity. London: Academic Press Ltd., 1993.
55. Tsien RY. The green fluorescent protein. Ann Rev Biochem 1998;67:509-44.
56. Aime S, Barge A, Botta M, Howard JAK, Kataky R, Lowe MP, et al. Dependence of the relaxivity and luminescence of gadolinium and europium amino-acid complexes on hydrogencarbonate and pH. Chem Commun 1999:1047-8.
57. Aime S, Barge A, Castelli DD, Fedeli F, Mortillaro A, Nielsen FU, et al. Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn Reson Med 2002;47:639-48.
58. Zhang S, Winter P, Wu K, Sherry AD. A novel Europium(III)-based MRI contrast agent. J Am Chem Soc 2001;123:1517-8.
59. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotech 2000;18:321-5.
60. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, et al. In vivo magnetic resonance imaging of transgene expression. Nature Med 2000;6:351-4.
61. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003;49:403-8.